The role of TNF-α in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide

Modern Rheumatology

Volumn 24, Issue 1, 2014, Pages 120-128

  Oharaseki, Toshiaki ^a   Yokouchi, Yuki ^a   Yamada, Hitomi ^a   Mamada, Hiroshi ^b   Muto, Satoshi ^b   Sadamoto, Kiyomi ^b   Miura, Noriko ^c   Ohno, Naohito ^c   Saji, Tsutomu ^d   Naoe, Shiro ^a   Takahashi, Kei ^a  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Arteritis; Arteritis model; Candida albicans; Kawasaki disease; Tumor necrosis factor

Indexed keywords

ETANERCEPT; INFLIXIMAB; POLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FUNGAL CELL WALL; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTERITIS; CANDIDA ALBICANS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; MICE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDIUM; POLYSACCHARIDES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905010997     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.854061     Document Type: Article

References (31)

1. Kawasaki T. Acute febrile muco-cutaneous lymph node syndrome in young children with unique digital desquamation (clinical observation of 50 cases observed at our institution). Allergy. 1967;16:178-222.
2. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991;41:785-97.
3. Wang GB, Li CR, Yang J, Wen PQ, Jia SL. A regulatory polymorphism in promoter region of TNFR1 gene is associated with Kawasaki disease in Chinese individuals. Hum Immunol. 2011;72:451-7.
4. Arj-Ong S, Thakkinstian A, McEvoy M, Attia J. A systematic review and meta-Analysis of tumor necrosis factor a-308 polymorphism and Kawasaki disease. Pediatr Int. 2010;52:527-32.
5. Kamizono S, Yamada A, Higuchi T, Kato H, Itoh K. Analysis of tumor necrosis factor-Alpha production and polymorphisms of the tumor necrosis factor-Alpha gene in individuals with a history of Kawasaki disease. Pediatr Int. 1999;41:341-5.
6. Quasney MW, Bronstein DE, Cantor RM, Zhang Q, Newburger JW, Burns JC, et al. Increased frequency of alleles associated with elevated tumor necrosis factor-Alpha levels in children with Kawasaki disease. Pediatr Res. 2001;49:686-90.
7. Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr. 1994;124:721-5.
8. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Yabuta K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48:247-51.
9. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous immunoglobulin for Kawasaki disease. Lancet. 1984;2:1055-8.
10. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol. 2012;22:216-21.
11. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004;31:804-10.
12. Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;58:644-9.
13. Saji T, Kemmotsu Y. Infliximab for Kawasaki syndrome. J Pediatr. 2006;149:426.
14. Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. JRheumatol. 2012;39:864-7.
15. Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res. 2009;65:696-701.
16. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr. 2010;157:960-6.
17. Murata H. Experimental Candida-induced arteritis in mice, relation to arteritis in the mucocutaneous lymph node syndrome. Microbiol Immunol. 1979;23:825-31.
18. Takahashi K, Oharaseki T, Wakayama M, Yokouchi Y, Naoe S, Murata H. Histopathological features of murine systemic vasculitis caused by Candida albicans extract - an animal model of Kawasaki disease. Inflamm Res. 2004;53:72-4.
19. Miura NN, Komai M, Adachi Y, Osada N, Kameoka Y, Suzuki K, et al. IL-10 is a negative regulatory factor of CAWS-vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice. J Immunol. 2009;183:3417-24.
20. Oharaseki T, Kameoka Y, Kura F, Persad AS, Suzuki K, Naoe S. Susceptibility loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans-derived substances. Microbiol Immunol. 2005;49:181-9.
21. Takahashi K, Oharaseki T, Yokouchi Y, Miura NN, Ohno N, Okawara AI, et al. Administration of human immunoglobulin suppresses development of murine systemic vasculitis induced with Candida albicans water-soluble fraction: an animal model of Kawasaki disease. Mod Rheumatol. 2010;20:160-7.
22. Takahashi K, Oharaseki T, Nagao T, Yokouchi Y, Yamada H, Nagi-Miura N, et al. Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease. Pediatr Rheumatol Online J. 2011;29:30.
23. Ohno N. Chemistry and biology of angiitis inducer, Candida albicans water-soluble mannoprotein-beta-glucan complex (CAWS). Microbiol Immunol. 2003;47:479-90.
24. Lehman TJ, Walker SM, Mahnovski V, McCurdy D. Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum. 1985;28:652-9.
25. Hui-Yuen JS, Duong TT, Yeung RS. TNF-A is necessary for induction of coronary artery inflammation and aneurysm formation in animal model of Kawasaki disease. Immunology. 2006;176:6294-301.
26. Lentsch AB, Ward PA. Regulation of inflammatory vascular damage. J Pathol. 2000;190:343-8.
27. Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010;20:86-9.
28. Wollin M, Abele S, Bruns H, Weyand M, Kalden JR, Spriewald BM, et al. Inhibition of TNF-Alpha reduces transplant arteriosclerosis in a murine aortic transplant model. Transpl Int. 2009;22:342-9.
29. Deveci F, Muz MH, Ilhan N, Kirkil G, Turgut T, Akpolat N. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Respirology. 2008;13:488-97.
30. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 2004;18(676-82):31-112.
31. Althur L. Efficacy and safety of the anti-TNF biologic agent. Mod Rheumatol. 2004;14:101-12.